**TPG Acquires 35% Stake in SCHOTT Poonawalla Joint Venture**
**Meta Description:** TPG has signed a deal to acquire a 35% stake in SCHOTT Poonawalla from Serum Institute of India, enhancing the joint venture’s growth potential.
**URL Slug:** tpg-acquires-schott-poonawalla-stake
**TPG Acquires 35% Stake in SCHOTT Poonawalla Joint Venture**
US private equity firm TPG has finalized a binding agreement to purchase a 35% stake in the SCHOTT Poonawalla joint venture from the Serum Institute of India (SII). The announcement was made on Tuesday, with TPG Growth, the firm’s middle market and growth equity platform, leading the investment alongside co-investor Novo Holdings. Following this transaction, SII will maintain a minority stake in SCHOTT Poonawalla. The total investment from TPG and Novo Holdings is reported to be $300 million.
This partnership is expected to bolster the joint venture’s capabilities, providing additional resources and strategic insights to support its long-term global ambitions. The deal is anticipated to close in the first half of 2025. The joint venture was established in 2021 between the Serum Institute of India and SCHOTT Pharma, a German leader in drug containment and delivery solutions.
Adar Poonawalla, CEO of Serum Institute of India, expressed enthusiasm about the partnership, stating, “Partnering with TPG marks an important step for us. Their experience in healthcare investing and global network make them a strong partner as we scale and explore new opportunities.” He emphasized that the collaboration with SCHOTT Pharma would continue, ensuring supply chain resilience and fostering innovation in vaccine packaging and delivery.
Ashok Saxena, managing director of SCHOTT Poonawalla, noted the increasing demand from pharmaceutical customers for advanced drug delivery and discovery solutions. He stated, “We are excited to welcome TPG onboard as an investor, and are confident that their proven track record of successfully driving healthcare businesses in the Indian market will greatly benefit SCHOTT Poonawalla.”
SCHOTT Poonawalla specializes in designing advanced drug containment and delivery solutions for pharmaceutical and biotechnology clients. Its product portfolio includes cartridges for auto-injector pens, prefillable syringes for various biologics, vials, ampoules, and regulatory services for biotech and pharmaceutical companies, as well as contract development and manufacturing organizations. SCHOTT Pharma, which serves over 1,800 customers, reported revenues of €957 million in FY24.
Bhushan Bopardikar, a business unit partner at TPG Growth, expressed excitement about the partnership, stating, “We are thrilled to partner with SCHOTT Pharma and Serum Institute of India to enhance SCHOTT Poonawalla’s market leadership as India’s largest injectables-focused drug containment solutions company.” He added that TPG’s local market expertise and strong presence in the Indian healthcare sector would complement SCHOTT Pharma’s innovation capabilities.
**FAQ**
**What is the significance of TPG’s investment in SCHOTT Poonawalla?**
TPG’s investment is significant as it provides SCHOTT Poonawalla with additional resources and strategic insights, enabling the joint venture to scale and enhance its position in the pharmaceutical market.
